Neural ECM in addiction, schizophrenia, and mood disorder

Progress in Brain Research

Volumn 214, Issue , 2014, Pages 263-284

  Lubbers, Bart R ^a   Smit, August B ^a   Spijker, Sabine ^a   van den Oever, Michel C ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Bipolar disorder; Drug addiction; Extracellular matrix; Major depressive disorder; Matrix metalloproteinases; Neural plasticity; Perineuronal net; Psychiatric disorders; Schizophrenia; Tissue plasminogen activator

Indexed keywords

ALCOHOL; OPIATE; PSYCHOSTIMULANT AGENT; REELIN;

ADDICTION; ARTICLE; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; DRUG DEPENDENCE; EXTRACELLULAR MATRIX; HUMAN; MOOD DISORDER; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA;

EID: 84922278342     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63486-3.00012-8     Document Type: Chapter

References (118)

1. Bahi A., Dreyer J.L. Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization. Genes Brain Behav. 2008, 7:244-256.
2. Bahi A., Dreyer J.L. Involvement of tissue plasminogen activator "tPA" in ethanol-induced locomotor sensitization and conditioned-place preference. Behav. Brain Res. 2012, 226:250-258.
3. Bahi A., Kusnecov A., Dreyer J.L. The role of tissue-type plasminogen activator system in amphetamine-induced conditional place preference extinction and reinstatement. Neuropsychopharmacology 2008, 33:2726-2734.
4. Bambico F.R., Belzung C. Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis?. Curr. Top. Behav. Neurosci. 2013, 15:243-291.
5. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology (Berl.) 2000, 153:31-43.
6. Berretta S. Extracellular matrix abnormalities in schizophrenia. Neuropharmacology 2012, 62:1584-1597.
7. Bitanihirwe B.K., Woo T.U. Perineuronal nets and schizophrenia: the importance of neuronal coatings. Neurosci. Biobehav. Rev. 2014, 45:85-99.
8. Bjorklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30:194-202.
9. Brown T.E., Forquer M.R., Cocking D.L., Jansen H.T., Harding J.W., Sorg B.A. Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference. Learn. Mem. 2007, 14:214-223.
10. Brown T.E., Forquer M.R., Harding J.W., Wright J.W., Sorg B.A. Increase in matrix metalloproteinase-9 levels in the rat medial prefrontal cortex after cocaine reinstatement of conditioned place preference. Synapse 2008, 62:886-889.
11. Campo C.G., Sinagra M., Verrier D., Manzoni O.J., Chavis P. Reelin secreted by GABAergic neurons regulates glutamate receptor homeostasis. PLoS One 2009, 4:e5505.
12. Carulli D., Rhodes K.E., Brown D.J., Bonnert T.P., Pollack S.J., Oliver K., et al. Composition of perineuronal nets in the adult rat cerebellum and the cellular origin of their components. J. Comp. Neurol. 2006, 494:559-577.
13. Celio M.R., Spreafico R., De Biasi S., Vitellaro-Zuccarello L. Perineuronal nets: past and present. Trends Neurosci. 1998, 21:510-515.
14. Chadwick B., Miller M.L., Hurd Y.L. Cannabis use during adolescent development: susceptibility to psychiatric illness. Front. Psychiatry 2013, 4:129.
15. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50:71-83.
16. Chen J., Repunte-Canonigo V., Kawamura T., Lefebvre C., Shin W., Howell L.L., et al. Hypothalamic proteoglycan syndecan-3 is a novel cocaine addiction resilience factor. Nat. Commun. 2013, 4:1955.
17. Cichon S., Muhleisen T.W., Degenhardt F.A., Mattheisen M., Miro X., Strohmaier J., et al. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am. J. Hum. Genet. 2011, 88:372-381.
18. Coleman L.G., Liu W., Oguz I., Styner M., Crews F.T. Adolescent binge ethanol treatment alters adult brain regional volumes, cortical extracellular matrix protein and behavioral flexibility. Pharmacol. Biochem. Behav. 2014, 116:142-151.
19. Conant K., Lonskaya I., Szklarczyk A., Krall C., Steiner J., Maguire-Zeiss K., et al. Methamphetamine-associated cleavage of the synaptic adhesion molecule intercellular adhesion molecule-5. J. Neurochem. 2011, 118:521-532.
20. Deepa S.S., Carulli D., Galtrey C., Rhodes K., Fukuda J., Mikami T., et al. Composition of perineuronal net extracellular matrix in rat brain: a different disaccharide composition for the net-associated proteoglycans. J. Biol. Chem. 2006, 281:17789-17800.
21. Dityatev A., Schachner M., Sonderegger P. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. Nat. Rev. Neurosci. 2010, 11:735-746.
22. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999, 35(Suppl.):S93-S100.
23. Ethell I.M., Ethell D.W. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J. Neurosci. Res. 2007, 85:2813-2823.
24. Fatemi S.H., Earle J.A., Mcmenomy T. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol. Psychiatry 2000, 5:654-663. 571.
25. Fatemi S.H., Stary J.M., Earle J.A., Araghi-Niknam M., Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67kDa and Reelin proteins in cerebellum. Schizophr. Res. 2005, 72:109-122.
26. Folsom T.D., Fatemi S.H. The involvement of Reelin in neurodevelopmental disorders. Neuropharmacology 2013, 68:122-135.
27. Frischknecht R., Gundelfinger E.D. The brain's extracellular matrix and its role in synaptic plasticity. Adv. Exp. Med. Biol. 2012, 970:153-171.
28. Frotscher M. Role for Reelin in stabilizing cortical architecture. Trends Neurosci. 2010, 33:407-414.
29. Fukakusa A., Nagai T., Mizoguchi H., Otsuka N., Kimura H., Kamei H., et al. Role of tissue plasminogen activator in the sensitization of methamphetamine-induced dopamine release in the nucleus accumbens. J. Neurochem. 2008, 105:436-444.
30. Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry 1998, 65:446-453.
31. Gasbarri A., Packard M.G., Campana E., Pacitti C. Anterograde and retrograde tracing of projections from the ventral tegmental area to the hippocampal formation in the rat. Brain Res. Bull. 1994, 33:445-452.
32. Glantz L.A., Lewis D.A. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch. Gen. Psychiatry 1997, 54:943-952.
33. Goes F.S., Willour V.L., Zandi P.P., Belmonte P.L., Mackinnon D.F., Mondimore F.M., et al. Sex-specific association of the Reelin gene with bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:549-553.
34. Gogolla N., Caroni P., Luthi A., Herry C. Perineuronal nets protect fear memories from erasure. Science 2009, 325:1258-1261.
35. Green A.I. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J. Clin. Psychiatry 2005, 66(Suppl. 6):21-26.
36. Gregg L., Barrowclough C., Haddock G. Reasons for increased substance use in psychosis. Clin. Psychol. Rev. 2007, 27:494-510.
37. Grillon C., Ameli R., Charney D.S., Krystal J., Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry 1992, 32:939-943.
38. Groc L., Choquet D., Stephenson F.A., Verrier D., Manzoni O.J., Chavis P. NMDA receptor surface trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein Reelin. J. Neurosci. 2007, 27:10165-10175.
39. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 2000, 57:1061-1069.
40. Gundelfinger E.D., Frischknecht R., Choquet D., Heine M. Converting juvenile into adult plasticity: a role for the brain's extracellular matrix. Eur. J. Neurosci. 2010, 31:2156-2165.
41. Halim N.D., Weickert C.S., Mcclintock B.W., Hyde T.M., Weinberger D.R., Kleinman J.E., et al. Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. Mol. Psychiatry 2003, 8:797-810.
42. Hashimoto T., Kajii Y., Nishikawa T. Psychotomimetic-induction of tissue plasminogen activator mRNA in corticostriatal neurons in rat brain. Eur. J. Neurosci. 1998, 10:3387-3399.
43. Heimel J.A., Van Versendaal D., Levelt C.N. The role of GABAergic inhibition in ocular dominance plasticity. Neural Plast. 2011, 2011:391763.
44. Hensch T.K. Critical period plasticity in local cortical circuits. Nat. Rev. Neurosci. 2005, 6:877-888.
45. Host L., Anglard P., Romieu P., Thibault C., Dembele D., Aunis D., et al. Inhibition of histone deacetylases in rats self-administering cocaine regulates lissencephaly gene-1 and reelin gene expression, as revealed by microarray technique. J. Neurochem. 2010, 113:236-247.
46. Iafrati J., Orejarena M.J., Lassalle O., Bouamrane L., Chavis P. Reelin, an extracellular matrix protein linked to early onset psychiatric diseases, drives postnatal development of the prefrontal cortex via GluN2B-NMDARs and the mTOR pathway. Mol. Psychiatry 2014, 19:417-426.
47. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15718-15723.
48. Kalivas P.W., O'brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008, 33:166-180.
49. Kalivas P.W., Volkow N.D. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol. Psychiatry 2011, 16:974-986.
50. Kolluri N., Sun Z., Sampson A.R., Lewis D.A. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am. J. Psychiatry 2005, 162:1200-1202.
51. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24:97-129.
52. Langan C., Mcdonald C. Neurobiological trait abnormalities in bipolar disorder. Mol. Psychiatry 2009, 14:833-846.
53. Levelt C.N., Hubener M. Critical-period plasticity in the visual cortex. Annu. Rev. Neurosci. 2012, 35:309-330.
54. Lewis D.A., Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 2008, 33:141-165.
55. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 2002, 25:409-432.
56. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6:312-324.
57. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
58. Liu W.S., Pesold C., Rodriguez M.A., Carboni G., Auta J., Lacor P., et al. Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouse. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3477-3482.
59. Luscher C., Malenka R.C. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 2011, 69:650-663.
60. Lussier A.L., Caruncho H.J., Kalynchuk L.E. Repeated exposure to corticosterone, but not restraint, decreases the number of reelin-positive cells in the adult rat hippocampus. Neurosci. Lett. 2009, 460:170-174.
61. Lussier A.L., Romay-Tallon R., Kalynchuk L.E., Caruncho H.J. Reelin as a putative vulnerability factor for depression: examining the depressogenic effects of repeated corticosterone in heterozygous reeler mice. Neuropharmacology 2011, 60:1064-1074.
62. Maiya R., Zhou Y., Norris E.H., Kreek M.J., Strickland S. Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1983-1988.
63. Marenco S., Weinberger D.R. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol. 2000, 12:501-527.
64. Martinowich K., Schloesser R.J., Manji H.K. Bipolar disorder: from genes to behavior pathways. J. Clin. Invest. 2009, 119:726-736.
65. Mauney S.A., Athanas K.M., Pantazopoulos H., Shaskan N., Passeri E., Berretta S., et al. Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. Biol. Psychiatry 2013, 74:427-435.
66. Mcrae P.A., Porter B.E. The perineuronal net component of the extracellular matrix in plasticity and epilepsy. Neurochem. Int. 2012, 61:963-972.
67. Melchor J.P., Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 2005, 93:655-660.
68. Miro X., Meier S., Dreisow M.L., Frank J., Strohmaier J., Breuer R., et al. Studies in humans and mice implicate neurocan in the etiology of mania. Am. J. Psychiatry 2012, 169:982-990.
69. Mizoguchi H., Yamada K., Niwa M., Mouri A., Mizuno T., Noda Y., et al. Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. J. Neurochem. 2007, 100:1579-1588.
70. Muhleisen T.W., Mattheisen M., Strohmaier J., Degenhardt F., Priebe L., Schultz C.C., et al. Association between schizophrenia and common variation in neurocan (NCAN), a genetic risk factor for bipolar disorder. Schizophr. Res. 2012, 138:69-73.
71. Murray R.M., O'callaghan E., Castle D.J., Lewis S.W. A neurodevelopmental approach to the classification of schizophrenia. Schizophr. Bull. 1992, 18:319-332.
72. Nagai T., Yamada K., Yoshimura M., Ishikawa K., Miyamoto Y., Hashimoto K., et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3650-3655.
73. Nagai T., Kamei H., Ito M., Hashimoto K., Takuma K., Nabeshima T., et al. Modification by the tissue plasminogen activator-plasmin system of morphine-induced dopamine release and hyperlocomotion, but not anti-nociceptive effect in mice. J. Neurochem. 2005, 93:1272-1279.
74. Nagai T., Noda Y., Ishikawa K., Miyamoto Y., Yoshimura M., Ito M., et al. The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J. Neurochem. 2005, 92:660-667.
75. Nagai T., Ito M., Nakamichi N., Mizoguchi H., Kamei H., Fukakusa A., et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J. Neurosci. 2006, 26:12374-12383.
76. Nakamoto K., Kawasaki S., Kobori T., Fujita-Hamabe W., Mizoguchi H., Yamada K., et al. Involvement of matrix metalloproteinase-9 in the development of morphine tolerance. Eur. J. Pharmacol. 2012, 683:86-92.
77. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
78. Niwa M., Yan Y., Nabeshima T. Genes and molecules that can potentiate or attenuate psychostimulant dependence: relevance of data from animal models to human addiction. Ann. N. Y. Acad. Sci. 2008, 1141:76-95.
79. Numachi Y., Yoshida S., Yamashita M., Fujiyama K., Naka M., Matsuoka H., et al. Psychostimulant alters expression of DNA methyltransferase mRNA in the rat brain. Ann. N. Y. Acad. Sci. 2004, 1025:102-109.
80. Ovadia G., Shifman S. The genetic variation of RELN expression in schizophrenia and bipolar disorder. PLoS One 2011, 6:e19955.
81. Pantazopoulos H., Woo T.U., Lim M.P., Lange N., Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch. Gen. Psychiatry 2010, 67:155-166.
82. Pantazopoulos H., Boyer-Boiteau A., Holbrook E.H., Jang W., Hahn C.G., Arnold S.E., et al. Proteoglycan abnormalities in olfactory epithelium tissue from subjects diagnosed with schizophrenia. Schizophr. Res. 2013, 150:366-372.
83. Pawlak R., Melchor J.P., Matys T., Skrzypiec A.E., Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:443-448.
84. Picchioni M.M., Murray R.M. Schizophrenia. BMJ 2007, 335:91-95.
85. Pietersen C.Y., Mauney S.A., Kim S.S., Lim M.P., Rooney R.J., Goldstein J.M., et al. Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia. J. Neurogenet. 2014, 28:53-69.
86. Pizzorusso T., Medini P., Berardi N., Chierzi S., Fawcett J.W., Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. Science 2002, 298:1248-1251.
87. Robinson T.E., Kolb B. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 2004, 47(Suppl. 1):33-46.
88. Russo S.J., Dietz D.M., Dumitriu D., Morrison J.H., Malenka R.C., Nestler E.J. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 2010, 33:267-276.
89. Saal D., Dong Y., Bonci A., Malenka R.C. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003, 37:577-582.
90. Savitz J.B., Price J.L., Drevets W.C. Neuropathological and neuromorphometric abnormalities in bipolar disorder: view from the medial prefrontal cortical network. Neurosci. Biobehav. Rev. 2014, 42C:132-147.
91. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr. Opin. Neurobiol. 1997, 7:191-197.
92. Schultz C.C., Muhleisen T.W., Nenadic I., Koch K., Wagner G., Schachtzabel C., et al. Common variation in NCAN, a risk factor for bipolar disorder and schizophrenia, influences local cortical folding in schizophrenia. Psychol. Med. 2014, 44:811-820.
93. See R.E. Neural substrates (amygdala) of cocaine-cue associations that trigger relapse. Eur. J. Pharmacol. 2005, 526:140-146.
94. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003, 168:3-20.
95. Skrzypiec A.E., Maiya R., Chen Z., Pawlak R., Strickland S. Plasmin-mediated degradation of laminin gamma-1 is critical for ethanol-induced neurodegeneration. Biol. Psychiatry 2009, 66:785-794.
96. Smith A.W., Nealey K.A., Wright J.W., Walker B.M. Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systems. Neurobiol. Learn. Mem. 2011, 96:199-206.
97. Spolidoro M., Sale A., Berardi N., Maffei L. Plasticity in the adult brain: lessons from the visual system. Exp. Brain Res. 2009, 192:335-341.
98. Stafford D., Lesage M.G., Glowa J.R. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology (Berl.) 1998, 139:169-184.
99. Stranahan A.M., Erion J.R., Wosiski-Kuhn M. Reelin signaling in development, maintenance, and plasticity of neural networks. Ageing Res. Rev. 2013, 12:815-822.
100. Sun Y., Farzan F., Barr M.S., Kirihara K., Fitzgerald P.B., Light G.A., et al. Gamma oscillations in schizophrenia: mechanisms and clinical significance. Brain Res. 2011, 1413:98-114.
101. Tamura H., Ishikawa Y., Shiosaka S. Does extracellular proteolysis control mammalian cognition?. Rev. Neurosci. 2013, 24:365-374.
102. Teixeira C.M., Martin E.D., Sahun I., Masachs N., Pujadas L., Corvelo A., et al. Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder. Neuropsychopharmacology 2011, 36:2395-2405.
103. Tueting P., Doueiri M.S., Guidotti A., Davis J.M., Costa E. Reelin down-regulation in mice and psychosis endophenotypes. Neurosci. Biobehav. Rev. 2006, 30:1065-1077.
104. Van Den Oever M.C., Lubbers B.R., Goriounova N.A., Li K.W., Van Der Schors R.C., Loos M., et al. Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking. Neuropsychopharmacology 2010, 35:2120-2133.
105. Van Den Oever M.C., Spijker S., Smit A.B. The synaptic pathology of drug addiction. Adv. Exp. Med. Biol. 2012, 970:469-491.
106. Vanderschuren L.J., Pierce R.C. Sensitization processes in drug addiction. Curr. Top. Behav. Neurosci. 2010, 3:179-195.
107. Veldic M., Kadriu B., Maloku E., Agis-Balboa R.C., Guidotti A., Davis J.M., et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr. Res. 2007, 91:51-61.
108. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91:439-442.
109. Wlodarczyk J., Mukhina I., Kaczmarek L., Dityatev A. Extracellular matrix molecules, their receptors, and secreted proteases in synaptic plasticity. Dev. Neurobiol. 2011, 71:1040-1053.
110. Woo T.U. Neurobiology of schizophrenia onset. Curr. Top. Behav. Neurosci. 2013.
111. Wright J.W., Harding J.W. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast. 2009, 2009:579382.
112. Wright J.W., Masino A.J., Reichert J.R., Turner G.D., Meighan S.E., Meighan P.C., et al. Ethanol-induced impairment of spatial memory and brain matrix metalloproteinases. Brain Res. 2003, 963:252-261.
113. Xue Y.X., Xue L.F., Liu J.F., He J., Deng J.H., Sun S.C., et al. Depletion of perineuronal nets in the amygdala to enhance the erasure of drug memories. J. Neurosci. 2014, 34:6647-6658.
114. Yamada K. Endogenous modulators for drug dependence. Biol. Pharm. Bull. 2008, 31:1635-1638.
115. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell. Mol. Life Sci. 2000, 57:276-289.
116. Yan Y., Yamada K., Mizoguchi H., Noda Y., Nagai T., Nitta A., et al. Reinforcing effects of morphine are reduced in tissue plasminogen activator-knockout mice. Neuroscience 2007, 146:50-59.
117. Zhou X.H., Brakebusch C., Matthies H., Oohashi T., Hirsch E., Moser M., et al. Neurocan is dispensable for brain development. Mol. Cell. Biol. 2001, 21:5970-5978.
118. Zimmermann D.R., Dours-Zimmermann M.T. Extracellular matrix of the central nervous system: from neglect to challenge. Histochem. Cell Biol. 2008, 130:635-653.